Xtandi to drive prostate cancer treatment market value to $8.2 Billion by 2023

The global treatment market value for prostate cancer, excluding hormonal and bone therapies, will expand more than threefold from $2.6 billion in 2013 to an estimated $8.2 billion by 2023, according to research and consulting firm GlobalData.

The company’s latest report, PharmaPoint: Prostate Cancer – Global Drug Forecast and Market Analysis to 2023, states that this increase, which will occur across the nine major markets of the US, France, Germany, Italy, Spain, UK, Japan, Brazil, and Canada, will be driven by a rapidly aging population, the introduction of nine new, premium-priced therapies by 2023, and the expected label extensions for both Zytiga and Xtandi in the treatment of hormone-sensitive prostate cancer.

Furthermore, Raksha Mudbhary, Ph.D., GlobalData’s Senior Analyst covering Oncology, says that Japan and Brazil will experience particularly impressive market growth during the forecast period, due to the increased screening of prostate cancer resulting in higher incidence in Japan, as well as the introduction of several branded products for the treatment of castration-resistant prostate cancer (CRPC).

Primary driver of growth will be the label extension of Xtandi

However, the analyst notes that the primary driver of growth across the nine major markets for prostate cancer treatment will be the label extension of Xtandi into chemotherapy-naïve metastatic CRPC, non-metastatic CRPC and hormone-sensitive prostate cancer.

Mudbhary explains: “Xtandi’s safety and efficacy garnered a favourable impression from Key Opinion Leaders, and its use in multiple prostate cancer patient segments ensures that it will be the market-leading drug in this therapy area by 2016.

“GlobalData forecasts that sales of Xtandi will grow to $3.8 billion by 2023, at a CAGR of 24%, accounting for an impressive 46% of total branded drug sales in the prostate cancer space.”

Despite the positive outlook over the forecast period, a few factors may limit growth, primarily the loss of patent protection for Zytiga, the leading drug in the prostate cancer therapeutics market in 2013. 

The analyst continues: “Zytiga is anticipated to lose key US patent protection in December 2016. Although there is some uncertainty regarding the timing of Zytiga generics entering the US market, the resulting loss of branded sales will restrict growth during the latter part of the forecast period.”